Open Trials

Name

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

A Phase 1 Study of Non-viral, RNA Modified GD2 Directed CAR T Cell Therapy for Patients with Recurrent or Refractory Neuroblastoma

Engineered Neuroblastoma Cellular ImmunoTherapy (ENCIT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma using Autologous T-cells lentivirally transduced to express CD171-specific CARs.

Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies

Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA): A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Intracranial administration of T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-positive tumors of the central nervous system (iCAR)

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

TCR-Alpha/Beta and CD19+ depleted KIR/KIR ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zolendronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

A two cohort pilot study of the tocilizumab optimization timing for CART19 (CTL019) associated cytokine release syndrome (CRS) management in pediatric patients with CD19 expressing relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)

Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2

A Phase 1 study of 131-I mIBG followed by Nivolumab and ch14.18/CHO in children with relapsed/refractory neuroblastoma

A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma

CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19Positive B Acute Lymphoblastic Leukemia

Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2-Positive Recurrent/Refractory Pediatric Central Nervous System Tumors

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Pediatric and young adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T cells with a fully human binding domain for CD19+ Leukemia or Lymphoma

Phase 1 Study of EGFR806-Specific CAR T Cell Locoregional Immunotherapy for EGFR-Positive Recurrent or Refractory Pediatric Central Nervous System Tumors

Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T cells (huCART19) for Very High-Risk Subsets of B cell Acute Lymphoblastic Leukemia (B-ALL)

Treatment of CMV infections with viral-specific T cells against CMV in pediatric and adult immunocompromised patients or recipients of allogeneic stem cell transplantation

A Phase I dose escalation study evaluating safety and tolerability of Viral-specific T cells against CMV in Adult Kidney Transplant Recipients

GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Sarcoma and Neuroblastoma to Increase Systemic Tumor Exposure

Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (BrainChild-03)

Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Chilren and young Adults with Relatpsed/Refractory AML